Venus Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Venus Remedies reported strong Q1 FY26 results with consolidated revenue from operations rising to ₹131.90 Cr from ₹108.61 Cr in Q1 FY25, a year-on-year growth of about 21%. Standalone revenue grew 25% to ₹131.85 Cr. Net profit surged to ₹9.60 Cr consolidated (from ₹1.22 Cr) and ₹11.69 Cr standalone (from ₹4.45 Cr), translating to an EPS of ₹7.18 consolidated and ₹8.76 standalone. EBITDA improved to ₹18.80 Cr from ₹12.85 Cr, with operating margins expanding. The auditor issued an unqualified limited review but flagged an Emphasis of Matter on two concerns: the German subsidiary Venus Pharma GmbH's net worth has turned negative by ₹295.40 lakhs, raising going concern doubts, and ₹2,859.72 lakhs in share application money to that subsidiary remains pending allotment. Management says the subsidiary's position will stabilize by end of FY 25-26 via restructuring of European operations.
Strong headline numbers — broad-based revenue and profit growth with margin expansion — are a clear positive for shareholders. However, the going concern flag on the German subsidiary and large unrecovered share application money are red flags worth monitoring, though management expects resolution through European restructuring in FY 25-26. Short-term stock may react positively to the earnings beat, with the subsidiary overhang limiting upside.